Year: 2020
Language: English
Author(s): World Federation of Hemophilia
Format: Video
We are still learning about gene therapy. Each patient experience is different, and gene therapy is not for everyone – either by choice or by exclusion because of the antibodies.
In this session from the WFH 2020 Virtual Summit, Debra Pollard, John Pasi, David Page, Garrett Hayes, Rob Schroeder and Enrique Preza Hernandez discuss: What can we expect if we ARE eligible – what is it like to participate in the gene therapy trials? What is it like to be a patient once you have gone through the treatment? What if it does not work for me (one and done) – can I try other future therapies?
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel
In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing
In this session from the WFH 2020 Virtual Summit, Barbara Konkle, Alfonso Iorio & Catherine Lambert will discuss & highlight
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor
With regulatory approval of the first gene therapy product expected, there is an urgent need for a mechanism to collect